Results 71 to 80 of about 204,699 (375)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials [PDF]

, 2013
Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack of consensus on appropriate outcome measures for reliably assessing treatment response.
Antoniou, K, Baughman, RP, Brown, KK, Castelino, FV, Christmann, RB, Christopher-Stine, L, Collard, HR, Cottin, V, Danoff, S, Dellaripa, PF, Denton, CP, Distler, O, Fischer, A, Flaherty, KR, Frankel, S, Highland, KB, Hummers, L, Huscher, D, Khanna, D, Kim, DS, Kowal-Bielecka, OM, LeSage, D, Lynch, DA, Matteson, EL, Merkel, PA, Miller, FW, Mittoo, S, Oddis, CV, Phillips, K, Pittrow, D, Proudman, SM, Richeldi, L, Ryu, JH, Saketkoo, LA, Sandorfi, N, Sarver, C, Seibold, JR, Shah, AA, Strand, V, Swigris, J, Wells, AU   +40 more
core   +1 more source

Angiotensin II type 1 and 2 receptors and lymphatic vessels modulate lung remodeling and fibrosis in systemic sclerosis and idiopathic pulmonary fibrosis

Clinics, 2014
OBJECTIVE: To validate the importance of the angiotensin II receptor isotypes and the lymphatic vessels in systemic sclerosis and idiopathic pulmonary fibrosis.
Edwin Roger Parra, Aline Domingos Pinto Ruppert, Vera Luiza Capelozzi   +2 more
doaj   +1 more source

Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

Trials, 2022
Background and rationale Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available.
Shu-guang Yang, Xue-qing Yu, Jian-sheng Li, Yang Xie, Wei Zhang, Chengjun Ban, Jihong Feng, Lei Wu, Xuechao Lu, Limin Zhao, Yong Meng, Miao Zhou, Yong He, Weixian Luo   +13 more
doaj   +1 more source

The treatment of idiopathic pulmonary fibrosis [PDF]

F1000Prime Reports, 2014
Idiopathic pulmonary fibrosis (IPF) is a progressive and invariably fatal disease with a median survival of less than three years from diagnosis. The last decade has seen an exponential increase in clinical trial activity in IPF and this in turn has led to important developments in the treatment of this terrible disease. Previous therapeutic approaches
Woodcock, HV, Maher, TM
openaire   +5 more sources

Diffuse pulmonary hemosiderosis after exposure to pesticides - A case report [PDF]

, 1998
This report describes the clinical, radiological, microscopical and ligandohistochemical findings in a 17-year-old woman who suffered from an acute onset of pulmonary hemosiderosis after inhalation of pesticides used for the cultivation of strawberries ...
Altiner, Mithat, Gabius, Hans-Joachim, Kayser, Klaus, Plodziszewska, Monika, Slodkowska, Janina, Waitr, Elzbieta   +5 more
core   +1 more source

Exacerbation of idiopathic pulmonary fibrosis [PDF]

Terapevticheskii arkhiv, 2020
Idiopathic pulmonary fibrosis (IPF) is usually characterized by a chronic and slowly progressive course. According to several studies, a small number of patients with IPF (about 515%) develops an acute deterioration of deasese exacerbation of IPF. Exacerbations of IPF can occur at any time of the disease and sometimes becomes the first manifestation ...
S. N. Avdeev, V. V. Gaynitdinova, Z. M. Merzhoeva, G. V. Neklyudova, N. A. Tsareva, G. S. Nuralieva   +5 more
openaire   +4 more sources

Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? [PDF]

, 2016
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and multiple internal organs and severe functional and structural microvascular alterations.
Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +1 more
core   +2 more sources

Heterogeneity of Rheumatoid Arthritis‐Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations with Disease Outcomes

Arthritis Care &Research, Accepted Article.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis‐associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999‐2021. RA‐ILD patients were
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib

Respirology Case Reports, 2020
Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after ...
Ryosuke Imai, Yutaka Tomishima
doaj   +1 more source

SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis

Nature Communications, 2023
The activation and accumulation of lung fibroblasts resulting in aberrant deposition of extracellular matrix components, is a pathogenic hallmark of Idiopathic Pulmonary Fibrosis, a lethal and incurable disease.
Ilianna Barbayianni, Paraskevi Kanellopoulou, Dionysios Fanidis, Dimitris Nastos, Eleftheria-Dimitra Ntouskou, Apostolos Galaris, Vaggelis Harokopos, Pantelis Hatzis, Eliza Tsitoura, Robert Homer, Naftali Kaminski, Katerina M. Antoniou, Bruno Crestani, Argyrios Tzouvelekis, Vassilis Aidinis   +14 more
doaj   +1 more source